PTC Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
Go back to PTC Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update
March 1, 2016 9:13 AM EST
Jefferies analyst, Gena Wang, cut her PT on TC Therapeutics (NASDAQ: PTCT) after hearing more color on the RTF letter and German pricing status on the 4Q15 earnings call. Consistent with her thesis, the FDA questioned ataluren effectiveness in DMD leaving... More
March 1, 2016 8:54 AM EST
RBC Capital analyst, Simos Simeonidis, cut the PT on PTC Therapeutics (NASDAQ: PTCT) to $9 from $11 after the company disclosed that FDA issued the Refuse-to-File letter because it views both the Phase IIb and the ACT DMD trials as "negative" and not providing "substantial... More
March 1, 2016 7:29 AM EST
Wedbush downgraded PTC Therapeutics (NASDAQ: PTCT) from Outperform to Neutral with a price target of $11.00 (from $27.00), saying lower Translarna estimates shift risk/reward.
Analyst Heather Behanna commented, "Though we still believe Translarna has a good chance of full EU approval, we are... More
March 1, 2016 7:27 AM EST
Cowen downgraded PTC Therapeutics (NASDAQ: PTCT) from Outperform to Market Perform.
For an analyst ratings summary and ratings history on PTC Therapeutics click here. For more ratings news on PTC Therapeutics click here.
Shares of PTC Therapeutics closed at $7.98 yesterday.
...
More
